News

Filter

Current filters:

LyxumiaDiabetes

1 to 9 of 19 results

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

05-12-2013

Results of a 24-week Phase IIIb clinical study showed that French drug major Sanofi’s diabetes drug…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show

05-10-2013

Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi temporarily pulls lixisenatide NDA in USA

12-09-2013

French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi's once-daily diabetes drug Lyxumia approved in Europe

04-02-2013

French drug major Sanofi (Euronext: SAN) this morning announced that the European Commission has granted…

DiabetesEuropeLyxumiaPharmaceuticalRegulationSanofi

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"

23-11-2012

The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

1 to 9 of 19 results

Back to top